Cargando…

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

OBJECTIVE: Reactivation of the hepatitis B virus (HBV) refers to an increase in HBV replication in a patient with inactive or resolved HBV. In this retrospective study, our aim is to present and compare HBV reactivation in multiple myeloma (MM) patients who received lenalidomide and/or bortezomib at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ataca Atilla, Pınar, Yalçıner, Merih, Atilla, Erden, İdilman, Ramazan, Beksaç, Meral
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863023/ https://www.ncbi.nlm.nih.gov/pubmed/31368290 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0103

Ejemplares similares

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
por: Atilla, Pinar Ataca, et al.
Publicado: (2022)

New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
por: Gunduz, Mehmet, et al.
Publicado: (2021)

Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia
por: Atilla, Erden, et al.
Publicado: (2015)

Prospective Analysis of Hemorrhagic Cystitis and BK Viremia in Allogeneic Hematopoietic Stem Cell Transplantation
por: Atilla, Erden, et al.
Publicado: (2020)

Successful Desensitization of a Patient with Rituximab Hypersensitivity
por: Ataca, Pinar, et al.
Publicado: (2015)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
por: Zhou, Liang
Publicado: (2022)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone
por: Yasui, Taku, et al.
Publicado: (2020)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
por: Leleu, X, et al.
Publicado: (2017)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
por: Ito, Shigeki, et al.
Publicado: (2013)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
por: Narsipur, Nihal, et al.
Publicado: (2021)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Aspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell Transplantation
por: Ataca, Pinar, et al.
Publicado: (2015)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
por: McCaughan, Georgia J., et al.
Publicado: (2022)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

P969: COMPARISON OF VENOUS THROMBOEMBOLISM INCIDENCE IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE-BASED REGIMENS WITH RIVAROXABAN OR ASPIRIN THROMBOPROPHYLAXIS
por: Wang, Y., et al.
Publicado: (2022)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
por: Mian, Hira, et al.
Publicado: (2022)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0522fc7flauq50svecqr4enofg